All we need to know about lipoprotein(a)

Area of Science:

• Cardiology
• Genetics
• Preventive Medicine

Background:

• Lipoprotein(a) [Lp(a)] is a genetically determined macromolecular complex.
• Lp(a) is independently and causally linked to atherosclerotic cardiovascular disease (ASCVD) and calcific aortic stenosis.
• Proposed mechanisms include proinflammatory, prothrombotic, and proatherogenic pathways.

Purpose of the Study:

• To highlight the significance of Lipoprotein(a) [Lp(a)] in cardiovascular risk assessment.
• To discuss the evolving landscape of Lp(a) testing and its implications for ASCVD prevention.
• To review emerging targeted therapies for Lp(a) reduction.

Main Methods:

• Review of current guidelines and emerging clinical investigations.
• Analysis of Lp(a)'s role in primary and secondary ASCVD prevention.
• Discussion of risk stratification tools and therapeutic interventions.

Main Results:

• Lp(a) measurement standardization is improving, with guidelines supporting lifetime testing for ASCVD risk prediction.
• Emerging Lp(a)-lowering therapies are under clinical investigation for cardiovascular benefit.
• Cascade screening for first-degree relatives of individuals with high Lp(a) is recommended.

Conclusions:

• Testing for Lipoprotein(a) [Lp(a)] is crucial for comprehensive ASCVD risk assessment.
• High Lp(a) levels warrant consideration of coronary calcium scoring and intensified risk factor management.
• For secondary prevention patients, adding PCSK9 inhibition to statin therapy may be considered in the presence of high Lp(a).